Beta Bionics (BBNX) CPO Mike Mensinger Sells 2,650 Shares

What Happened
Mike Mensinger, Chief Product Officer of Beta Bionics (BBNX), sold 2,650 shares on 2026-09-16 at $22.00 per share, generating $58,300 in proceeds. The sale was executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-16; reported on Form 4 filed 2026-09-17 (timely filing).
• Trade: Sale of 2,650 shares at $22.00 each; total proceeds $58,300.
• Method: Sale under a Rule 10b5-1 plan (Plan adopted September 8, 2025).
• Filing status: Not indicated as late; filed the next day.
• Shares owned after transaction: Not specified in the provided filing details.
• Transaction code: S = Sale.

Context
A Rule 10b5-1 plan allows insiders to sell shares under pre-set instructions and is commonly used to avoid concerns about trading on nonpublic information. Sales under such plans are generally considered routine and do not, by themselves, indicate a change in the insider’s view of the company. Purchases tend to be more informative about insider sentiment than routine sales.